AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'

By Lauraann Wood · June 8, 2020, 7:02 PM EDT

Humira buyers have alleged neither an antitrust violation nor an antitrust injury in their novel lawsuit claiming AbbVie built a "patent thicket" around its immunosuppressant drug Humira to block cheaper biosimilars...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re: Humira (Adalimumab) Antitrust Litigation

Case Number

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

March 18, 2019

Recent Articles By Lauraann

November 07, 2024
Ill. Judge Anticipates 'Massive' Outcome Investor Restitution
November 04, 2024
MultiPlan Judge Raises Eyebrows At Attys' Biz Flight Billing
October 31, 2024
Ill. Judge Doubts Hillrom's Bid For Rival's Communications
October 18, 2024
Ill. Justices Find Broad COVID Immunity For Health Facilities
October 15, 2024
Horizon Lodges 4-Fold Attack On Tepezza MDL Bellwethers
September 23, 2024
Edelson, Susman, Berger To Lead MultiPlan Collusion MDL
September 19, 2024
Outcome Exec Who Flipped Gets 7 Months For $1B Fraud Role
September 18, 2024
7th Circ. Questions Nixing $183M Eli Lilly Drug Rebate Verdict
September 04, 2024
Ill. Panel Backs Atty's Bid To Litigate Medical Record Fee Suit
August 21, 2024
Hillrom Says Funding Docs 'Plainly' Relevant In Antitrust Suit